The clinical resupply services will be delivered under AdAlta’s contract development and manufacturing Master Services Agreement with KBI Biopharma that was announced on 5 June 2018.
Selexis and KBI announced today that they have signed service agreements with Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting canc...